Press coverage about Myovant Sciences (NYSE:MYOV) has trended somewhat positive on Sunday, according to Accern. The research group scores the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Myovant Sciences earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave news articles about the company an impact score of 46.0394604776203 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Myovant Sciences (NYSE MYOV) opened at $13.15 on Friday. Myovant Sciences has a 52-week low of $9.92 and a 52-week high of $18.85.
A number of equities research analysts have commented on the stock. Zacks Investment Research raised shares of Myovant Sciences from a “sell” rating to a “hold” rating in a research report on Thursday, August 31st. Cowen reissued a “buy” rating on shares of Myovant Sciences in a research report on Tuesday, October 3rd. Robert W. Baird reissued a “buy” rating and issued a $20.00 price objective on shares of Myovant Sciences in a research report on Wednesday, October 4th. JMP Securities reaffirmed an “outperform” rating and issued a $25.00 target price (up from $23.00) on shares of Myovant Sciences in a research report on Wednesday, October 4th. Finally, Evercore ISI began coverage on shares of Myovant Sciences in a research report on Wednesday, August 16th. They issued an “outperform” rating on the stock. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. Myovant Sciences currently has a consensus rating of “Buy” and an average price target of $22.50.
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.
What are top analysts saying about Myovant Sciences Ltd? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Myovant Sciences Ltd and related companies.